FLUCELVAX QUAD (Seqirus Pty Ltd)
Product name
FLUCELVAX QUAD
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
188 (255 working days)
Active ingredients
influenza virus haemagglutinin
Registration type
EOI
Indication
FLUCELVAX QUAD (suspension for injection) is indicated for the prevention of influenza caused by Influenza Virus, Types A and B contained in the vaccine. The vaccine is now also indicated for use in adults and children 2 years of age and older.
For full details regarding recommendations for influenza vaccination, please refer to the relevant national immunisation guidelines.